华人健康
(301408)
| 流通市值：18.03亿 | | | 总市值：48.36亿 |
| 流通股本：1.49亿 | | | 总股本：4.00亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,269,282,916.66 | 2,167,417,364.99 | 1,104,366,687.97 | 3,797,160,297.68 |
| 营业收入 | 3,269,282,916.66 | 2,167,417,364.99 | 1,104,366,687.97 | 3,797,160,297.68 |
| 利息收入 | - | 0 | - | - |
| 已赚保费 | - | 0 | 0 | 0 |
| 手续费及佣金收入 | - | 0 | 0 | 0 |
| 二、营业总成本 | 3,133,754,849.95 | 2,072,607,532.09 | 1,032,719,031.44 | 3,656,977,275.19 |
| 营业成本 | 2,209,430,174 | 1,476,841,935.6 | 741,621,514.46 | 2,633,730,658.54 |
| 利息支出 | - | 0 | 0 | 0 |
| 手续费及佣金支出 | - | 0 | 0 | 0 |
| 退保金 | - | 0 | 0 | 0 |
| 赔付支出净额 | - | 0 | 0 | 0 |
| 提取保险合同准备金净额 | - | 0 | 0 | 0 |
| 保单红利支出 | - | 0 | 0 | 0 |
| 分保费用 | - | 0 | 0 | 0 |
| 税金及附加 | 15,612,408.1 | 10,227,955.2 | 4,984,516.12 | 16,717,939.16 |
| 销售费用 | 728,529,767.28 | 467,504,701.63 | 229,475,919.98 | 804,473,521.27 |
| 管理费用 | 141,170,914.53 | 92,504,960.96 | 45,542,950.9 | 158,510,878.46 |
| 研发费用 | 21,099,674.53 | 15,401,262.49 | 6,196,651.12 | 24,194,023.68 |
| 财务费用 | 17,911,911.51 | 10,126,716.21 | 4,897,478.86 | 19,350,254.08 |
| 其中:利息费用 | 12,987,925.89 | 6,472,401.11 | 4,245,297.67 | 12,242,661.36 |
| 其中:利息收入 | 11,114,680.83 | 8,900,804.58 | 4,626,783.53 | 14,066,684.55 |
| 加:公允价值变动收益 | 387.7 | 0 | 13,770.24 | 33,945.6 |
| 加:投资收益 | 1,251,299.74 | 634,983.53 | 246,761.45 | 770,340.21 |
| 净敞口套期收益 | - | 0 | 0 | 0 |
| 汇兑收益 | - | 0 | 0 | 0 |
| 资产处置收益 | 2,073,118.56 | 831,072.31 | 637,289.25 | 1,044,827.91 |
| 资产减值损失(新) | -5,237,593.08 | -4,809,086.7 | -1,606,455.64 | -6,864,244.99 |
| 信用减值损失(新) | -4,081,720.74 | -1,968,677.97 | -4,866,976.71 | -4,589,274.45 |
| 其他收益 | 19,569,312.01 | 13,234,419.31 | 3,329,428 | 22,144,774.67 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 149,102,870.9 | 102,732,543.38 | 69,401,473.12 | 152,723,391.44 |
| 加:营业外收入 | 879,748.68 | 340,795.62 | 158,443.77 | 230,367.02 |
| 减:营业外支出 | 1,765,553.78 | 1,005,274.33 | 375,945.72 | 1,445,892.61 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 148,217,065.8 | 102,068,064.67 | 69,183,971.17 | 151,507,865.85 |
| 减:所得税费用 | 32,350,773.59 | 22,254,311.98 | 16,683,609.08 | 33,825,557.68 |
| 六、净利润 | 115,866,292.21 | 79,813,752.69 | 52,500,362.09 | 117,682,308.17 |
| 持续经营净利润 | 115,866,292.21 | 79,813,752.69 | 52,500,362.09 | 117,682,308.17 |
| 终止经营净利润 | - | - | 0 | - |
| 归属于母公司股东的净利润 | 107,929,607.48 | 72,969,838.3 | 47,772,301.04 | 114,667,584.92 |
| 少数股东损益 | 7,936,684.73 | 6,843,914.39 | 4,728,061.05 | 3,014,723.25 |
| (一)基本每股收益 | 0.27 | 0.18 | 0.12 | 0.29 |
| (二)稀释每股收益 | 0.27 | 0.18 | 0.12 | 0.29 |
| 八、其他综合收益 | 300,897 | - | 0 | 2,134,785.55 |
| 归属于母公司股东的其他综合收益 | 300,897 | - | 0 | 2,134,785.55 |
| 九、综合收益总额 | 116,167,189.21 | 79,813,752.69 | 52,500,362.09 | 119,817,093.72 |
| 归属于母公司股东的综合收益总额 | 108,230,504.48 | 72,969,838.3 | 47,772,301.04 | 116,802,370.47 |
| 归属于少数股东的综合收益总额 | 7,936,684.73 | 6,843,914.39 | 4,728,061.05 | 3,014,723.25 |
| 公告日期 | 2024-10-29 | 2024-08-29 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |